MarketWatch.com - Top Stories

This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly

Verve Therapeutics’ stock rallies by a record 80% on Eli Lilly’s premium purchase price for the drug-development company.

Jun 17, 2025 - 13:24
 0
This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly
Verve Therapeutics’ stock rallies by a record 80% on Eli Lilly’s premium purchase price for the drug-development company.
Read More

Tags:

Previous Article

Ready to pay $1,000 a year for a premium credit card? New American Express Plati...

Next Article

U.S. Treasurys may be losing their safe-haven status — and these bonds could tak...

Related Posts

More SALT should be on America’s tax-deduction menu. Way more.

More SALT should be on America’s tax-deduction menu. Wa...

May 17, 2025  0

Premium travel perks like VIP lounges and rewards points offer less than they used to — but these upgrades are still worth it

Premium travel perks like VIP lounges and rewards point...

May 30, 2025  0

Why the stock market is going to love higher U.S. tariffs on China

Why the stock market is going to love higher U.S. tarif...

May 12, 2025  0